TY  - CHAP
AU  - Jozo Delic
AU  - Jean-Brice Marteau
AU  - Karim Maloum
AU  - Florence Nguyen-Khac
AU  - Frédéric Davi
AU  - Zahia Azgui
AU  - Véronique Leblond
AU  - Jacques-Louis Binet
AU  - Sylvie Chevillard
AU  - Hélène Merle-Béral
ED  - Pablo Oppezzo
Y1  - 2012-02-10
PY  - 2012
T1  - DNA Damage Response/Signaling and Genome (In)Stability as the New Reliable Biological Parameters Defining Clinical Feature of CLL
N2  - B-cell chronic lymphocytic leukemia (CLL) is considered a single disease with extremely variable course, and survival rates ranging from months to decades. It is clear that clinical heterogeneity reflects biologic diversity with at least two major subtypes in terms of cellular proliferation, clinical aggressiveness and prognosis. As CLL progresses, abnormal hematopoiesis results in pancitopenia and decreased immunoglobulin production, followed by nonspecific symptoms such as fatigue or malaise. A cure is usually not possible, and delayed treatment (until symptoms develop) is aimed at lengthening life and decreasing symptoms. Researchers are playing a lead role in investigating CLL's cause and the role of genetics in the pathogenesis of this disorder. Research programs are dedicated towards understanding the basic mechanisms underlying CLL with the hope of improving treatment options.
BT  - Chronic Lymphocytic Leukemia
SP  - Ch. 4
UR  - https://doi.org/10.5772/27819
DO  - 10.5772/27819
SN  - 
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-25
ER  -